

# 2019 Future of Burns R&D Pipeline Drugs and Companies- Analysis of Global Burns Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/24A07A6160FEN.html>

Date: January 2019

Pages: 75

Price: US\$ 2,199.00 (Single User License)

ID: 24A07A6160FEN

## Abstracts

The global demand for Burns treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Burns pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Burns pipeline companies from advancing their products into Phase 3 or Phase 4.

### Burns Report Description

The H1 2019 pipeline review report on Burns pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Burns pipeline compounds.

The Burns pipeline guide presents information on all active drugs currently being developed for Burns. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Burns

pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Burns drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Burns product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Burns pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Burns pipeline report includes

An overview of Burns disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator,

Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

## REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Burns pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Burns pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Burns pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### **1. TABLE OF CONTENTS**

- 1.1 List of Tables
- 1.2 List of Figures

### **2. GLOBAL BURNS PIPELINE OVERVIEW**

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

### **3. EXECUTIVE SUMMARY**

- 3.1 Burns Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Burns pipeline, H1- 2019
- 3.5 Mechanism of Action wise Burns Pipeline Candidates

### **4. AEGLE THERAPEUTICS BURNS PIPELINE DETAILS**

- 4.1 Aegle Therapeutics Business Profile
- 4.2 Aegle Therapeutics Burns Drug Details
  - 4.2.1 Drug Snapshot
    - 4.2.1.1 Originator
    - 4.2.1.2 Collaborator/Co-Developer
    - 4.2.1.3 Route of Administration
    - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 4.2.1.5 Area
    - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5. ALGIPHARMA AS BURNS PIPELINE DETAILS**

- 5.1 AlgiPharma AS Business Profile
- 5.2 AlgiPharma AS Burns Drug Details
  - 5.2.1 Drug Snapshot
    - 5.2.1.1 Originator
    - 5.2.1.2 Collaborator/Co-Developer
    - 5.2.1.3 Route of Administration
    - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 5.2.1.5 Area
    - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6. ALLIANCE PHARMA PLC BURNS PIPELINE DETAILS**

- 6.1 Alliance Pharma Plc Business Profile
- 6.2 Alliance Pharma Plc Burns Drug Details
  - 6.2.1 Drug Snapshot
    - 6.2.1.1 Originator
    - 6.2.1.2 Collaborator/Co-Developer
    - 6.2.1.3 Route of Administration
    - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 6.2.1.5 Area
    - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

## **7. AMARANTUS BIOSCIENCE HOLDINGS INC BURNS PIPELINE DETAILS**

- 7.1 Amaranthus Bioscience Holdings Inc Business Profile
- 7.2 Amaranthus Bioscience Holdings Inc Burns Drug Details
  - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

## **8. AMKOR PHARMA BURNS PIPELINE DETAILS**

- 8.1 Amkor Pharma Business Profile
- 8.2 Amkor Pharma Burns Drug Details
  - 8.2.1 Drug Snapshot
    - 8.2.1.1 Originator
    - 8.2.1.2 Collaborator/Co-Developer
    - 8.2.1.3 Route of Administration
    - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 8.2.1.5 Area
    - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

## **9. BIOHARMONY THERAPEUTICS INC BURNS PIPELINE DETAILS**

- 9.1 Bioharmony Therapeutics Inc Business Profile
- 9.2 Bioharmony Therapeutics Inc Burns Drug Details
  - 9.2.1 Drug Snapshot
    - 9.2.1.1 Originator
    - 9.2.1.2 Collaborator/Co-Developer
    - 9.2.1.3 Route of Administration
    - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 9.2.1.5 Area

- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

## **10. CFM PHARMA HOLDING BV BURNS PIPELINE DETAILS**

- 10.1 CFM Pharma Holding BV Business Profile
- 10.2 CFM Pharma Holding BV Burns Drug Details
  - 10.2.1 Drug Snapshot
    - 10.2.1.1 Originator
    - 10.2.1.2 Collaborator/Co-Developer
    - 10.2.1.3 Route of Administration
    - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 10.2.1.5 Area
    - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

## **11. DESTINY PHARMA PLC BURNS PIPELINE DETAILS**

- 11.1 Destiny Pharma Plc Business Profile
- 11.2 Destiny Pharma Plc Burns Drug Details
  - 11.2.1 Drug Snapshot
    - 11.2.1.1 Originator
    - 11.2.1.2 Collaborator/Co-Developer
    - 11.2.1.3 Route of Administration
    - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 11.2.1.5 Area
    - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

## **12. ENERGENESIS BIOMEDICAL CO LTD BURNS PIPELINE DETAILS**

- 12.1 Energenesis Biomedical Co Ltd Business Profile
- 12.2 Energenesis Biomedical Co Ltd Burns Drug Details
  - 12.2.1 Drug Snapshot
    - 12.2.1.1 Originator
    - 12.2.1.2 Collaborator/Co-Developer
    - 12.2.1.3 Route of Administration
    - 12.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 12.2.1.5 Area
    - 12.2.1.6 Type of Molecular Entity
- 12.3 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

## **13. GNT PHARMA CO LTD BURNS PIPELINE DETAILS**

- 13.1 GNT Pharma Co Ltd Business Profile
- 13.2 GNT Pharma Co Ltd Burns Drug Details
  - 13.2.1 Drug Snapshot
    - 13.2.1.1 Originator
    - 13.2.1.2 Collaborator/Co-Developer
    - 13.2.1.3 Route of Administration
    - 13.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 13.2.1.5 Area
    - 13.2.1.6 Type of Molecular Entity
- 13.3 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

## **14. HYPO-STREAM LTD BURNS PIPELINE DETAILS**

- 14.1 Hypo-Stream Ltd Business Profile



## 14.2 Hypo-Stream Ltd Burns Drug Details

### 14.2.1 Drug Snapshot

#### 14.2.1.1 Originator

#### 14.2.1.2 Collaborator/Co-Developer

#### 14.2.1.3 Route of Administration

#### 14.2.1.4 Orphan Drug/Fast Track/Special Designation

#### 14.2.1.5 Area

#### 14.2.1.6 Type of Molecular Entity

## 14.3 Current Status

## 14.4 Drug Overview

## 14.5 Drug Mechanism of Action

## 14.6 Clinical/Pre-clinical Trial Details

## 14.7 Latest Drug Developments

## **15. MADAM THERAPEUTICS BV BURNS PIPELINE DETAILS**

### 15.1 Madam Therapeutics BV Business Profile

### 15.2 Madam Therapeutics BV Burns Drug Details

#### 15.2.1 Drug Snapshot

#### 15.2.1.1 Originator

#### 15.2.1.2 Collaborator/Co-Developer

#### 15.2.1.3 Route of Administration

#### 15.2.1.4 Orphan Drug/Fast Track/Special Designation

#### 15.2.1.5 Area

#### 15.2.1.6 Type of Molecular Entity

## 15.3 Current Status

## 15.4 Drug Overview

## 15.5 Drug Mechanism of Action

## 15.6 Clinical/Pre-clinical Trial Details

## 15.7 Latest Drug Developments

## **16. MALLINCKRODT PLC BURNS PIPELINE DETAILS**

### 16.1 Mallinckrodt Plc Business Profile

### 16.2 Mallinckrodt Plc Burns Drug Details

#### 16.2.1 Drug Snapshot

#### 16.2.1.1 Originator

#### 16.2.1.2 Collaborator/Co-Developer

#### 16.2.1.3 Route of Administration

- 16.2.1.4 Orphan Drug/Fast Track/Special Designation
- 16.2.1.5 Area
- 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

## **17. MEDIWOUND LTD BURNS PIPELINE DETAILS**

- 17.1 MediWound Ltd Business Profile
- 17.2 MediWound Ltd Burns Drug Details
  - 17.2.1 Drug Snapshot
    - 17.2.1.1 Originator
    - 17.2.1.2 Collaborator/Co-Developer
    - 17.2.1.3 Route of Administration
    - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 17.2.1.5 Area
    - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

## **18. NEOMATRIX THERAPEUTICS INC BURNS PIPELINE DETAILS**

- 18.1 NeoMatrix Therapeutics Inc Business Profile
- 18.2 NeoMatrix Therapeutics Inc Burns Drug Details
  - 18.2.1 Drug Snapshot
    - 18.2.1.1 Originator
    - 18.2.1.2 Collaborator/Co-Developer
    - 18.2.1.3 Route of Administration
    - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 18.2.1.5 Area
    - 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status
- 18.4 Drug Overview

- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

## **19. NOVION TECHNOLOGIES INC BURNS PIPELINE DETAILS**

- 19.1 Novion Technologies Inc Business Profile
- 19.2 Novion Technologies Inc Burns Drug Details
  - 19.2.1 Drug Snapshot
    - 19.2.1.1 Originator
    - 19.2.1.2 Collaborator/Co-Developer
    - 19.2.1.3 Route of Administration
    - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 19.2.1.5 Area
    - 19.2.1.6 Type of Molecular Entity
- 19.3 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

## **20. PHAGELUX INC BURNS PIPELINE DETAILS**

- 20.1 Phagelux Inc Business Profile
- 20.2 Phagelux Inc Burns Drug Details
  - 20.2.1 Drug Snapshot
    - 20.2.1.1 Originator
    - 20.2.1.2 Collaborator/Co-Developer
    - 20.2.1.3 Route of Administration
    - 20.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 20.2.1.5 Area
    - 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

## **21. RIPTIDE BIOSCIENCE INC BURNS PIPELINE DETAILS**

- 21.1 Riptide Bioscience Inc Business Profile
- 21.2 Riptide Bioscience Inc Burns Drug Details
  - 21.2.1 Drug Snapshot
    - 21.2.1.1 Originator
    - 21.2.1.2 Collaborator/Co-Developer
    - 21.2.1.3 Route of Administration
    - 21.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 21.2.1.5 Area
    - 21.2.1.6 Type of Molecular Entity
- 21.3 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

## **22. ROJI LTD BURNS PIPELINE DETAILS**

- 22.1 Roji Ltd Business Profile
- 22.2 Roji Ltd Burns Drug Details
  - 22.2.1 Drug Snapshot
    - 22.2.1.1 Originator
    - 22.2.1.2 Collaborator/Co-Developer
    - 22.2.1.3 Route of Administration
    - 22.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 22.2.1.5 Area
    - 22.2.1.6 Type of Molecular Entity
- 22.3 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

## **23. SE-CURE PHARMACEUTICALS LTD BURNS PIPELINE DETAILS**

- 23.1 Se-cure Pharmaceuticals Ltd Business Profile
- 23.2 Se-cure Pharmaceuticals Ltd Burns Drug Details
  - 23.2.1 Drug Snapshot
    - 23.2.1.1 Originator

- 23.2.1.2 Collaborator/Co-Developer
- 23.2.1.3 Route of Administration
- 23.2.1.4 Orphan Drug/Fast Track/Special Designation
- 23.2.1.5 Area
- 23.2.1.6 Type of Molecular Entity
- 23.3 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

## **24. SEPHORIS PHARMACEUTICALS LLC BURNS PIPELINE DETAILS**

- 24.1 Sephoris Pharmaceuticals LLC Business Profile
- 24.2 Sephoris Pharmaceuticals LLC Burns Drug Details
  - 24.2.1 Drug Snapshot
    - 24.2.1.1 Originator
    - 24.2.1.2 Collaborator/Co-Developer
    - 24.2.1.3 Route of Administration
    - 24.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 24.2.1.5 Area
    - 24.2.1.6 Type of Molecular Entity
- 24.3 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

## **25. STEMENERGY THERAPEUTICS INC BURNS PIPELINE DETAILS**

- 25.1 Stemsynergy Therapeutics Inc Business Profile
- 25.2 Stemsynergy Therapeutics Inc Burns Drug Details
  - 25.2.1 Drug Snapshot
    - 25.2.1.1 Originator
    - 25.2.1.2 Collaborator/Co-Developer
    - 25.2.1.3 Route of Administration
    - 25.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 25.2.1.5 Area
    - 25.2.1.6 Type of Molecular Entity

- 25.3 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

## **26. TGV LABORATORIES INC BURNS PIPELINE DETAILS**

- 26.1 TGV Laboratories Inc Business Profile
- 26.2 TGV Laboratories Inc Burns Drug Details
  - 26.2.1 Drug Snapshot
    - 26.2.1.1 Originator
    - 26.2.1.2 Collaborator/Co-Developer
    - 26.2.1.3 Route of Administration
    - 26.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 26.2.1.5 Area
    - 26.2.1.6 Type of Molecular Entity
- 26.3 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

## **27. THERAPURE BIOPHARMA INC BURNS PIPELINE DETAILS**

- 27.1 Therapure Biopharma Inc Business Profile
- 27.2 Therapure Biopharma Inc Burns Drug Details
  - 27.2.1 Drug Snapshot
    - 27.2.1.1 Originator
    - 27.2.1.2 Collaborator/Co-Developer
    - 27.2.1.3 Route of Administration
    - 27.2.1.4 Orphan Drug/Fast Track/Special Designation
    - 27.2.1.5 Area
    - 27.2.1.6 Type of Molecular Entity
- 27.3 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

## **20. LATEST BURNS DRUG PIPELINE DEVELOPMENTS, 2019**

## **21. APPENDIX**

21.1 About Us

21.2 Sources and Methodology

21.3 Contact Information

## I would like to order

Product name: 2019 Future of Burns R&D Pipeline Drugs and Companies- Analysis of Global Burns Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/24A07A6160FEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/24A07A6160FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



